Literature DB >> 11418708

Difficult insulinoma.

J M Lawrence1, T Smith, D Iles, J P Reckless.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11418708      PMCID： PMC1281602          DOI： 10.1177/014107680109400710

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor.

Authors:  N A Samaan; F K Pham; R V Sellin; J F Fernandez; R S Benjamin
Journal:  Ann Intern Med       Date:  1990-09-01       Impact factor: 25.391

Review 2.  Octreotide in hyperinsulinism.

Authors:  R W Barrons
Journal:  Ann Pharmacother       Date:  1997-02       Impact factor: 3.154

3.  The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia.

Authors:  A O Hoff; R Vassilopoulou-Sellin
Journal:  Cancer       Date:  1998-04-15       Impact factor: 6.860

4.  Diazoxide treatment for insulinoma: a national UK survey.

Authors:  G V Gill; O Rauf; I A MacFarlane
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

5.  Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon.

Authors:  R Gama; V Marks; J Wright; J D Teale
Journal:  Clin Endocrinol (Oxf)       Date:  1995-07       Impact factor: 3.478
  5 in total
  2 in total

Review 1.  Malignant insulinoma: spectrum of unusual clinical features.

Authors:  Boaz Hirshberg; Craig Cochran; Monica C Skarulis; Steven K Libutti; H Richard Alexander; Bradford J Wood; Richard Chang; David E Kleiner; Phillip Gorden
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

2.  Proinsulin-secreting neuroendocrine tumor of the pancreas.

Authors:  A Piovesan; A Pia; G Visconti; M Terzolo; A Leone; G Magro; F Cesario; G Borretta
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.